Form 4: Elanco CEO Boosts Stake with DSU Acquisition

Jeffrey N. Simmons, Elanco Animal Health's President and CEO, acquired 129.2829 deferred stock units, increasing his total beneficial ownership to 18,099.5935 units.

Summary

• Jeffrey N. Simmons, President, CEO, and Director of Elanco Animal Health Inc. (ELAN), acquired 129.2829 Deferred Stock Units (DSUs).
• The transaction occurred on October 17, 2025.
• Each DSU represents the right to receive one share of Company common stock or its cash equivalent.
• The underlying common stock value at the time of acquisition was $21.42 per unit.
• Following this transaction, Mr. Simmons beneficially owns 18,099.5935 DSUs.
• These DSUs are scheduled to settle in cash or shares of common stock upon termination of employment or during a specified future year, as per the Executive Deferral and Stock Match Plan.

Sentiment

Score: 7

Explanation: The acquisition of deferred stock units by the CEO is generally a positive signal, indicating continued alignment of interests and confidence in the company. However, the relatively small size of the acquisition suggests it's likely a routine compensation grant rather than a significant discretionary investment.

Positives

• Increased alignment of management's interests with shareholders through additional equity ownership.
• Acquisition of deferred stock units by the CEO can signal confidence in the company's future performance.

Negatives

• The acquisition amount of 129.2829 units is relatively small in the context of total beneficial ownership, suggesting it might be a routine compensation grant rather than a significant discretionary purchase.

Risks

• The value of the deferred stock units is tied to the future performance of Elanco's common stock, exposing the holder to market fluctuations until settlement.
• Settlement of DSUs is contingent on future events (termination of employment or specified future year), introducing a time-based risk.

Future Outlook

Deferred Stock Units are expected to settle in cash or shares of Elanco Animal Health common stock following termination of employment or during a specified future year, in accordance with the Executive Deferral and Stock Match Plan.

Industry Context

This filing details an insider transaction specific to Elanco Animal Health's executive compensation and does not provide broader industry trends or context.

Stakeholder Impact

• Shareholders: Increased alignment of the CEO's financial interests with shareholder value.
• Employees: May signal stability and confidence from top leadership.

Next Steps

• Settlement of the deferred stock units upon termination of employment or during a specified future year, as per the Executive Deferral and Stock Match Plan.

Key Dates

Recommendation

This Form 4 filing details a routine acquisition of deferred stock units by the CEO as part of an executive compensation plan. While it indicates continued alignment of management's interests with shareholders, the transaction's size is not substantial enough to warrant a change in investment thesis or a strong buy/sell recommendation based solely on this filing. Investors should consider broader financial performance and strategic initiatives for a comprehensive investment decision.

Keywords

Elanco Animal Health, ELAN, Jeffrey N. Simmons, Deferred Stock Units, DSU, insider transaction, beneficial ownership, CEO, director, executive compensation